# Abuse-Deterrent Opioids-Evaluation and Labeling - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/abuse-deterrent-opioids-evaluation-and-labeling/cd0f4ddf-e4fc-4694-a929-33733fb8e8db

> FDA guidance document: Abuse-Deterrent Opioids-Evaluation and Labeling. Issue date: April 02, 2015. Get complete insights and analysis.

---

## Details

- Title: Abuse-Deterrent Opioids-Evaluation and Labeling
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2015-04-02
- Last Changed: 2022-02-17
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2013-D-0045">FDA-2013-D-0045</a>

## Related Documents

- [Orally Disintegrating Tablets:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/orally-disintegrating-tablets-guidance-for-industry/e9db30b4-68fc-445e-9286-7e4573fd1c00)
- [Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications](https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-summary-bioequivalence-data-for-abbreviated-new-drug-applications/c8804eda-e868-4190-aaf3-700e3b13cf9e)
- [ANDAs: Impurities in Drug Products:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/andas-impurities-in-drug-products-guidance-for-industry/1729c807-7b92-415c-a307-05a491b55e63)